SG11202012015YA - Compositions and methods for the modulation of adaptive immunity - Google Patents
Compositions and methods for the modulation of adaptive immunityInfo
- Publication number
- SG11202012015YA SG11202012015YA SG11202012015YA SG11202012015YA SG11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA SG 11202012015Y A SG11202012015Y A SG 11202012015YA
- Authority
- SG
- Singapore
- Prior art keywords
- modulation
- compositions
- methods
- adaptive immunity
- immunity
- Prior art date
Links
- 230000004721 adaptive immunity Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682276P | 2018-06-08 | 2018-06-08 | |
| PCT/US2019/036050 WO2019236998A1 (en) | 2018-06-08 | 2019-06-07 | Compositions and methods for the modulation of adaptive immunity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012015YA true SG11202012015YA (en) | 2021-01-28 |
Family
ID=68769461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012015YA SG11202012015YA (en) | 2018-06-08 | 2019-06-07 | Compositions and methods for the modulation of adaptive immunity |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190382759A1 (https=) |
| EP (1) | EP3801641A4 (https=) |
| JP (1) | JP2021526860A (https=) |
| KR (1) | KR20210060429A (https=) |
| CN (1) | CN113286619A (https=) |
| AU (1) | AU2019281006A1 (https=) |
| CA (1) | CA3102783A1 (https=) |
| SG (1) | SG11202012015YA (https=) |
| WO (1) | WO2019236998A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499805B2 (en) | 2010-06-18 | 2016-11-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for synthetic RNA endonucleases |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| JP2021526858A (ja) | 2018-06-08 | 2021-10-11 | ロックアネイビオ， インコーポレイテッド | Ｒｎａ標的化融合タンパク質組成物および使用方法 |
| AU2020208346B2 (en) | 2019-01-14 | 2026-01-29 | University Of Rochester | Targeted nuclear RNA cleavage and polyadenylation with CRISPR-cas |
| WO2021011504A1 (en) * | 2019-07-12 | 2021-01-21 | Duke University | Nanoparticle systems for targeted delivery of crispr/cas13 and methods of using same |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| CN113136376B (zh) * | 2021-05-26 | 2022-10-21 | 武汉大学 | 一种Cas12a变体及其在基因编辑中的应用 |
| WO2023150131A1 (en) * | 2022-02-01 | 2023-08-10 | The Regents Of The University Of California | Method of regulating alternative polyadenylation in rna |
| CN114848808B (zh) * | 2022-03-24 | 2023-04-25 | 四川大学 | 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用 |
| CN114720699A (zh) * | 2022-04-22 | 2022-07-08 | 浙江大学 | 一种结直肠癌早期预警血清指标及其检测方法和应用 |
| CN116949011A (zh) * | 2022-04-26 | 2023-10-27 | 中国科学院动物研究所 | 经分离的Cas13蛋白、基于它的基因编辑系统及其用途 |
| CN115068632A (zh) * | 2022-06-22 | 2022-09-20 | 华中科技大学同济医学院附属同济医院 | Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法 |
| WO2024264035A2 (en) * | 2023-06-22 | 2024-12-26 | The General Hospital Corporation | Compositions and methods of generating endogenous tdr molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019500899A (ja) * | 2015-11-23 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作 |
| EA201891338A1 (ru) * | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| US12180499B2 (en) * | 2016-10-31 | 2024-12-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for impeding transcription of expanded microsatellite repeats |
| AU2018234825B2 (en) * | 2017-03-15 | 2020-12-17 | Massachusetts Institute Of Technology | Novel CAS13B orthologues CRISPR enzymes and systems |
| US11168322B2 (en) * | 2017-06-30 | 2021-11-09 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
-
2019
- 2019-06-07 US US16/434,787 patent/US20190382759A1/en not_active Abandoned
- 2019-06-07 CA CA3102783A patent/CA3102783A1/en active Pending
- 2019-06-07 AU AU2019281006A patent/AU2019281006A1/en not_active Abandoned
- 2019-06-07 CN CN201980051039.7A patent/CN113286619A/zh active Pending
- 2019-06-07 KR KR1020217000507A patent/KR20210060429A/ko not_active Ceased
- 2019-06-07 JP JP2021518054A patent/JP2021526860A/ja active Pending
- 2019-06-07 SG SG11202012015YA patent/SG11202012015YA/en unknown
- 2019-06-07 EP EP19814000.6A patent/EP3801641A4/en active Pending
- 2019-06-07 WO PCT/US2019/036050 patent/WO2019236998A1/en not_active Ceased
-
2023
- 2023-11-09 US US18/505,709 patent/US20240344060A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240344060A1 (en) | 2024-10-17 |
| EP3801641A1 (en) | 2021-04-14 |
| WO2019236998A1 (en) | 2019-12-12 |
| CN113286619A (zh) | 2021-08-20 |
| US20190382759A1 (en) | 2019-12-19 |
| CA3102783A1 (en) | 2019-12-12 |
| JP2021526860A (ja) | 2021-10-11 |
| KR20210060429A (ko) | 2021-05-26 |
| EP3801641A4 (en) | 2022-09-28 |
| AU2019281006A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202012015YA (en) | Compositions and methods for the modulation of adaptive immunity | |
| IL280134A (en) | Anti-CD112R preparations and methods | |
| IL277079A (en) | Cartirin preparations and methods of use | |
| IL268970A (en) | New preparations and methods | |
| ES3063369T3 (en) | Carotenoid compositions and uses thereof | |
| SG10202001869VA (en) | Cd19 compositions and methods for immunotherapy | |
| SG11202101777VA (en) | Methods and compositions for the modification of plants | |
| GB202201860D0 (en) | Novel methods and compositions | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| WO2015120138A3 (en) | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF | |
| GB2578519B (en) | Compositions and methods and uses relating thereto | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| SG11202104448WA (en) | Compositions and methods | |
| IL266562A (en) | Methods and methods for adaptive immune regulation | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| GB201817444D0 (en) | Methods and compositions | |
| GB201815402D0 (en) | Compositions and methods and uses relating thereto | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| IL273699A (en) | Sulfazine salt preparations and methods of using them | |
| GB201819987D0 (en) | Methods and compositions | |
| GB201804092D0 (en) | Methods and compositions | |
| ZA202101361B (en) | Compositions and methods for treating the eye | |
| SG11202000612TA (en) | Methods and compositions for the treatment of melanoma | |
| SG11202012283XA (en) | Additive composition and method of preparing the same | |
| HK40049655A (en) | Compositions and methods for the modulation of adaptive immunity |